Cytel competitors

Marc’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GlaxoSmithKline (GSK), has given him extensive industry experience, including finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganisation; and business development. Marc is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, GPPS from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK Japan. He holds an MBA from HEC, Paris and a Bachelor of Law degree from Paris University.

Jamie Macdonald is Chief Executive Officer of Parexel. He has nearly 25 years of experience in leading global biopharmaceutical services companies. Prior to joining Parexel, Mr. Macdonald served as CEO of INC Research, now known as Syneos Health, from January 2013 through September 2016, where he led the company through a successful Initial Public Offering in 2014. Mr. Macdonald also served as INC’s Chief Operating Officer from July 2011 through December 2012, and previously held several leadership positions in the biopharmaceutical services industry, including Senior Vice President and Head of Global Project Management at Quintiles, now known as IQVIA. Prior to this, he held various senior operational and finance roles at Quintiles. He has previously served on the Board of Directors for the Association of Clinical Research Organizations (ACRO) and as its Chairman in 2015. Mr. Macdonald’s recent experience also includes serving as Chairman of the Board for Certara, a drug development consultancy with solutions spanning discovery, preclinical and clinical drug development, from 2017 to 2018. Mr. Macdonald began his career in the pharmaceutical industry with Syntex Corporation (acquired by Roche Holdings, Inc.). A native of Scotland, he holds a B.A. in Economics from Heriot-Watt University in Edinburgh, Scotland and is a qualified Chartered Management Accountant (ACMA).

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Chief Executive Officer | Board Director | Healthcare Technology | Software and Service Leader for HCIT and Life Sciences | McKinsey & Company | Veteran

Robert Munro is an expert in combining Human and Machine Intelligence, working with Machine Learning approaches to Text, Speech, Image and Video Processing. Robert has founded several AI companies, building some of the top teams in Artificial Intelligence. He has worked in many diverse environments, from Sierra Leone, Haiti and the Amazon, to London, Sydney and Silicon Valley, in organizations ranging from startups to the United Nations. He has shipped Machine Learning Products at startups and at/with Amazon, Google, IBM & Microsoft. Robert has published more than 50 papers on Artificial Intelligence and is a regular speaker about technology in an increasingly connected world. He has a PhD from Stanford University. Robert is the author of Human-in-the-Loop Machine Learning (Manning Publications, 2020)

Robert Davie is a Chief Executive Officer at Pharm Olam International and is based in Watford, Hertfordshire, United Kingdom. He has worked as VP/Gen Mgr:Global Clinical Development at COVANCE INC.

Mr. Manish Vinayak Soman is a President and Chief Executive Officer at Sciformix and is based in United States.